TY -的T1 wi相互传染风险的病人th bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01937-2017 VL - 51 IS - 1 SP - 1701937 AU - Chalmers, James D. AU - Ringshausen, Felix C. AU - Harris, Bridget AU - Elborn, J. Stuart AU - Posthumus, Annette AU - Haworth, Charles S. AU - Pilkington, Nicola AU - Polverino, Eva AU - Ruddy, Thomas AU - Aliberti, Stefano AU - Goeminne, Pieter C. AU - Winstanley, Craig AU - De Soyza, Anthony Y1 - 2018/01/01 UR - //www.qdcxjkg.com/content/51/1/1701937.abstract N2 - Involving patients in the design, conduct and dissemination of clinical research, clinical guidelines and education projects is highly beneficial, and is a priority for funders and societies such as the European Respiratory Society (ERS) [1]. Bronchiectasis is a lung condition associated with chronic cough and sputum production that is rapidly increasing in prevalence in Europe [2]. It is a neglected disease, but recent initiatives including the European Bronchiectasis Registry and research network (EMBARC) and the European Union supported European Reference Network for Rare Pulmonary Diseases (ERN-LUNG) are beginning to raise the diseases profile and stimulate new research [3, 4]. Patient involvement has been, and remains, central to these projects including the recently published European bronchiectasis guidelines which were developed with patients as members of the panel [5].Risks of cross-infection in bronchiectasis are small, and should not currently restrict access to specialised care http://ow.ly/dkVl30hcu5pWe acknowledge the EMBARC registry steering committee, the ERN-Lung bronchiectasis core network and ERN-Lung steering committee who approved this document. Bridget Harris, Nicola Pilkington, Annette Posthumus and Thomas Ruddy are representatives of the broader EMBARC/ELF bronchiectasis patient advisory group. ER -